Rubicon Research IPO Date, Review, Price, Allotment Details
The Rubicon Research IPO opens on October 9, 2025, and closes on October 13, 2025. It is a Book Built Issue, through which the company plans to raise approximately ₹1,377.50 crores, comprising a fresh issue of ₹500 crores and an offer for sale of 1,80,92,762 equity shares with a face value of ₹1 each.
The price band for the IPO is ₹461 to ₹485 per share, with the allocation as: Retail Investors – 10%, Qualified Institutional Buyers (QIBs) – 75%, and High Net Worth Individuals (HNIs) – 15%. The IPO is scheduled to list on BSE and NSE on October 16, 2025, with the allotment date on October 14, 2025.
Financially, Rubicon Research reported a revenue of ₹1,296.22 crores in 2025, up from ₹872.39 crores in 2024. The profit increased to ₹134.36 crores in 2025 from ₹91.01 crores in 2024. Based on these financials, the IPO may be considered suitable for long-term investment.
Rubicon Research IPO Details
Rubicon Research IPO Market Lot
The Rubicon Research IPO has a minimum market lot of 30 shares, requiring an application amount of ₹14,550. Retail investors can apply for up to 13 lots, totaling 390 shares with an application amount of ₹1,89,150.
IPO Reservation
Investor Category Share Offered -% Shares Anchor Investor – Shares -% QIB (Ex. Anchor) 85,06,804 Shares -% NII Shares Offered 42,54,299 Shares 27.21 Retail Shares Offered 28,36,200 Shares 18.14% Employee Shares Offered 40,046 Shares 0.26%
Rubicon Research IPO Anchor Investors
Rubicon Research IPO Dates
The Rubicon Research IPO opens on October 9, 2025, and closes on October 13, 2025. The allotment will be finalized on October 14, and the IPO is scheduled to list on October 16, 2025.
Promoters and Holding Pattern
The promoters of Rubicon Research are General Atlantic Singapore RR Pte. Ltd., Pratibha Pilgaonkar, Sudhir Dhirendra Pilgaonkar, Parag Suganchand Sancheti, Surabhi Parag Sancheti, and Sumant Sudhir Pilgaonkar.
Objects of the Issue & Utilisation of Proceeds
About Rubicon Research IPO
Rubicon Research is a leading pharmaceutical formulation company known for its strong focus on innovation through dedicated research and development. Its product portfolio features specialty formulations and drug–device combination products primarily targeting regulated markets, particularly the United States.
The company follows a multidisciplinary, data-driven, and ROI-focused product selection strategy designed to identify sustainable opportunities for new product development. It actively pursues high-potential areas by leveraging its expertise in development, manufacturing, and sales to expand market share.
Key strengths of Rubicon Research include being one of the fastest-growing Indian pharmaceutical companies among its peers, a data-backed product selection process, a robust R&D team, and a strong sales and distribution network in the U.S.
Rubicon Research IPO Company Financial Report
Amount in Crores (₹)
Rubicon Research IPO Valuation – FY2025
Check Rubicon Research IPO valuation details like Earning Per Share (EPS), Price/Earning (P/E) Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
Peer Group Comparison
IPO Lead Managers aka Merchant Bankers
- Axis Capital Ltd.
- IIFL Capital Services Ltd.
- JM Financial Ltd.
- SBI Capital Markets Ltd.
IPO Registrar
MUFG Intime India Pvt. Ltd.
Phone: +91-22-4918 6270
Email: rubicon.ipo@linkintime.co.in
Website: https://in.mpms.mufg.com/Initial_Offer/public-issues.html
Company Address
Rubicon Research Ltd.
MedOne House, B-75,
Road No. 33, Wagle Estate,
Thane, Maharashtra, 400604
Phone: 022 61414000
Email: investors@rubicon.co.in
Website: https://www.rubicon.co.in/